BioForce Nanosciences Net debt/EBITDA
Cos'è Net debt/EBITDA di BioForce Nanosciences?
Net debt/EBITDA di BioForce Nanosciences Holdings, Inc. è -13.80
Qual è la definizione di Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA di aziende nel Consumer Staples settore su OTC rispetto a BioForce Nanosciences
Cosa fa BioForce Nanosciences?
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. The company is based in Virginia Beach, Virginia.
Aziende con net debt/ebitda simili a BioForce Nanosciences
- Isabella Bank ha Net debt/EBITDA di -13.86
- Sinosoft Technology ha Net debt/EBITDA di -13.85
- Capita Plc ha Net debt/EBITDA di -13.84
- EGL ha Net debt/EBITDA di -13.82
- Atlas Pearls Ltd ha Net debt/EBITDA di -13.82
- Excelsior Mining ha Net debt/EBITDA di -13.81
- BioForce Nanosciences ha Net debt/EBITDA di -13.80
- Greenbrook TMS ha Net debt/EBITDA di -13.79
- Neogenomics ha Net debt/EBITDA di -13.78
- Onto Innovation ha Net debt/EBITDA di -13.78
- CBTX Inc ha Net debt/EBITDA di -13.76
- Christopher & Banks ha Net debt/EBITDA di -13.75
- Patagonia Gold ha Net debt/EBITDA di -13.74